Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug triapine studied in uterine cancer patients before hysterectomy

NCT ID NCT04494113

First seen Jan 08, 2026 · Last updated Jun 17, 2026 · Updated 31 times

Summary

This early-stage trial studies how the drug triapine affects uterine cancer cells in 12 women scheduled for hysterectomy. Participants receive triapine before surgery, and researchers measure changes in tumor markers from tissue samples. The goal is to understand if triapine can slow cancer growth, not to cure or control the disease long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ENDOMETRIAL SEROUS ADENOCARCINOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland, 21287, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida, 33146, United States

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida, 33442, United States

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida, 33324, United States

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida, 33136, United States

  • VCU Massey Comprehensive Cancer Center

    Richmond, Virginia, 23298, United States

Conditions

The condition(s) this trial relates to.

endometrial serous adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.